When was Enyo Pharma founded?

Enyo Pharma was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Enyo Pharma located?

Enyo Pharma is headquartered in Lyon, France.

How many employees does Enyo Pharma have?

As of Mar 01, 2026, the latest employee count at Enyo Pharma is 10 - 49.

Is Enyo Pharma a funded company?

Enyo Pharma is a funded company, having raised a total of $120M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2015.

When was the latest funding round of Enyo Pharma?

Enyo Pharma's latest funding was a $***** Series C round on Jun 12, 2025, with participation from 1 investor.

Where does Enyo Pharma rank among its competitors?

Enyo Pharma ranks 11th amongst 248 active competitors, of which 81 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Enyo Pharma?

Enyo Pharma's top competitors include Nimbus Therapeutics, Madrigal Pharmaceuticals and Akebia Therapeutics. Among them, Drug Farm secured the most recent funding round in July, 2026.

Enyo Pharma - 2026 Company Profile, Funding & Competitors

Enyo Pharma is a series C company based in Lyon (France), founded in 2014. It operates as a Developer of therapeutics for diseases with impaired kidney function. Enyo Pharma has raised $120M in funding from investors like Orbimed, Morningside and Sofinnova Partners. The company has 248 active competitors, including 81 funded and 67 that have exited. Its top competitors include companies like Nimbus Therapeutics, Madrigal Pharmaceuticals and Akebia Therapeutics.

Company Details

Developer of therapeutics for diseases with impaired kidney function. The company offers VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.

Website: www.enyopharma.com/
Social
Email ID: *****@enyopharma.com

Key Metrics

Founded Year

2014

Location

Lyon, France

Stage

Series C

Total Funding

$120M in 8 rounds

Latest Funding Round

Series C, Jun 12, 2025, $*****

Investors

Orbimed & 10 more

Ranked

11^th among 248 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Madrigal Pharmaceuticals & 207 more

View Enyo Pharma's full profile

Enyo Pharma has raised a total funding of $120M over 8 rounds. Its first funding round was on 2015. Its latest funding round was a Series C round on Jun 12, 2025 for $*****. 1 investor participated in its latest round. Enyo Pharma has 11 institutional investors.

Here is the list of recent funding rounds of Enyo Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 12, 2025	8504571	Series C	9500899	5834904	7268723	5982307
Jan 03, 2024	4886022	Series C	1889477	9736049	8661057	Andera Partners & 1 more
Oct 31, 2018	3697920	Grant (prize money)	8248745	1698655	4837139	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Enyo Pharma's funding rounds and investors

Enyo Pharma's employee count trend

Enyo Pharma has 10 - 49 employees as of Mar 26. Here is Enyo Pharma's employee count trend over the years:

Uncover Enyo Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enyo Pharma include Nimbus Therapeutics, Madrigal Pharmaceuticals and Akebia Therapeutics. Here is the list of Top 10 competitors of Enyo Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	66/100
3rd	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	65/100
4th	Ardelyx 2007, Fremont (United States), Public	Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases	$61.1M	Amgen Business Development, New Enterprise Associates ... & 11 others	65/100
5th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
6th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
7th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	64/100
8th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, VenBio & 10 others	64/100
9th	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, Loayal Valley Capital & 14 others	63/100
10th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	63/100
11th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	INNOBIO, Orbimed & 9 others	60/100